Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration

American Journal of Gastroenterology

Volumn 94, Issue 12, 1999, Pages 3583-3588

  Jensen, Donald M ^a   Krawitt, Edward L ^b   Keeffe, Emmet B ^c   Hollinger, F Blaine ^d   James, Stephen P ^e   Mullen, Kevin ^f   Everson, Gregory T ^g   Hoefs, John C ^h   Fromm, Hans ⁱ   Black, Martin ^j   Foust, Robert T ^k   Pimstone, Neville R ^l   Heathcote, E Jenny L ^m   Albert, Donald ⁿ  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^j TEMPLE UNIVERSITY HOSPITAL   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY HEALTH NETWORK   (Canada)

ⁿ AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032786260     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00710-8     Document Type: Article

References (20)

1. Tong M.J., El-Farra N.S., Reikes A.R., et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
2. Romeo R., Rumi M., Colombo M. Alfa interferon treatment of chronic hepatitis C. Biomed Pharmacother. 49:1995;111-115.
3. Tong M.J., Reddy K.R., Lee W.M., et al. Treatment of chronic hepatitis C with consensus interferon A multicenter, randomized, controlled trial . Hepatology. 26:1997;747-754.
4. Chemello L., Cavalletto L., Noventa F., et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C-treated with interferon-alfa. J Viral Hepatitis. 2:1995;91-96.
5. Yoshioka K., Higashi Y., Yamada M., et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver. 15:1995;57-62.
6. Yamada G., Takatani M., Kishi F., et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 22:1995;1351-1354.
7. Stuyver L., Rossau R., Wyseur A., et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 74:1993;1093-1102.
8. Simmonds P., Alberti P., Alter H.J., et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 19:1994;1321-1324. (letter).
9. Yun Z.B., Reichard O., Chen M., et al. Serum hepatitis C virus RNA levels in chronic hepatitis C - Importance for outcome of interferon treatment. Scand J Infect Dis. 26:1994;263-270.
10. Martinot-Peignoux M., Marcellin P., Pouteau M., et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.
11. Kobayashi Y., Watanabe S., Konishi M., et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology. 18:1993;1319-1325.
12. Aiyama T., Yoshioka K., Takayanagi M., et al. Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. J Hepatology. 23:1995;497-502.
13. Craxi A., Magrin S., Fabiano C., et al. Host and viral features in chronic HCV infection Relevance to interferon responsiveness . Res Virol. 146:1995;273-278.
14. Fried M.W., Hoofnagle J.H. Therapy of hepatitis C. Sem Liver Dis. 15:1995;82-91.
15. Yuki N., Hayashi N., Kasahara A., et al. Pretreatment viral load and response to prolonged interferon-alfa course for chronic hepatitis. Hepatology. 22:1995;457-463.
16. Hofmann H. Genotypes and virus load in patients with hepatitis C infection. Infection. 23:1995;133-138.
17. Lau J.Y.N., Mizokami M., Kolberg J.A., et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis. 171:1995;281-289.
18. Heathcote E.J., Keeffe E.B., Lee S.S., et al. Retreatment of chronic hepatitis C with consensus interferon. Hepatology. 27:1998;1136-1143.
19. Kohara M., Tanaka T., Tsukiyama-Kohara K., et al. Hepatitis c virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. J Infect Dis. 172:1995;934-938.
20. Blatt L.M., Davis J.M., Klein S.B., et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 16:1996;489-499.